UCB strengthens cardiovascular and metabolic product portfolio in Germany

Published: 24-Aug-2009
Regulatory Research & Development

UCB and Novartis have signed a licensing agreement for cardiovascular and diabetes products in Germany.


UCB and Novartis have signed a licensing agreement for cardiovascular and diabetes products in Germany.

Under the agreement, UCB has extended commercial rights to the cardiovascular drug Provas (valsartan) for the German market beyond 2011 and has licensed in commercial rights for anti-hypertension drugs Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).

UCB will also co-market two new oral anti-diabetics, Jalra and Icandra (vildagliptin and vildagliptin and metformin).

"With this agreement we are building on our strengths in Germany," said Willy Cnops, vice president of UCB and managing director of its German business.

"We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

UCB Germany is an affiliate of Belgian biopharmaceutical firm UCB, which focuses on medicines for central nervous system and immunology disorders.

  • Companies:
  • UCB
  • Novartis
See more

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

Read more
In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  3. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
  4. Kynos Therapeutics’ KMO inhibitor demonstrates safety and tolerability in Phase I study The lead drug candidate, KNS366, demonstrated its safety and tolerability in healthy adult participants in a Phase I trial
  5. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

MIT researchers to lead a new centre for continuous mRNA manufacturing

Faculty at the MIT are embarking upon a three-year research programme to design the world's first fully integrated, continuous mRNA manufacturing platform
Drug Delivery

Novartis publishes data on multiple sclerosis treatment

Data showed the sustained efficacy of continuous Kesimpta (ofatumumab) treatment over five years in patients with relapsing forms of multiple sclerosis (RMS)
Research & Development

Novartis and MMV move to Phase III study to treat uncomplicated malaria

As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination
Ingredients

Therapeutic: tislelizumab for oncology

With three main subtypes (adenocarcinoma, squamous cell carcinoma and large cell), non-small cell lung cancer is the predominant form of lung cancer
Ingredients

Therapeutic: zilucoplan for myasthenia gravis

The rare disease myasthenia gravis (MG) is an autoimmune condition that causes muscle weakness, particularly of those in the face, eyes and that control swallowing
Ingredients

Therapeutic: leniolisib for APDS

APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease
Subscribe now